Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 542665 | NSE Symbol : NEOGEN | ISIN : INE136S01016 | Industry : Chemicals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
25-Mar-2025	25-Mar-2025	Investments	Outcome of Board Meeting - Investment in Neogen Chemicals Japan Corporation Limited.
27-Jan-2025	01-Feb-2025	Quarterly Results	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2025 inter alia to consider and approve Un-audited financials for the quarter and nine months ended December 31 2024. Outcome of Board Meeting (As Per BSE Announcement Dated on: 01/02/2025)
06-Nov-2024	12-Nov-2024	Quarterly Results	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve Intimation of Board meeting scheduled to be held on November 122024. Board Meeting outcome Unaudited Financial Results Q2FY25 (As Per Bse Announcement Dated on 12.11.2024)
26-Oct-2024	26-Oct-2024	Revision in Directors Remuneration	Outcome of Board Meeting
01-Aug-2024	07-Aug-2024	Quarterly Results	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve Pursuant to regulation 29 and 33 of the Listing Regulations as amended from time to time notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday August 7 2024 inter-alia to consider approve and take on record the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30 2024. Outcome of Board Meeting held on 07-08-2024 (As Per BSE Announcement Dated on: 07/08/2024)
24-Apr-2024	30-Apr-2024	Accounts	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2024 inter alia to consider and approve Pursuant to regulation 29 and 33 of the Listing Regulations notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday April 30 2024 inter-alia to consider approve and take on record the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31 2024 and to consider recommendation of a final dividend if any on the equity shares of the Company for the financial year ended March 31 2024 subject to declaration and approval of the same by the shareholders at the ensuing Annual General Meeting Approval of Dividend of Rs. 2 per equity share by the Board of Directors of the Company. Outcome of Board meeting Approval of Scheme of Amalgamation of Buli Chemicals India Private Limited - WOS with Neogen Chemicals Limited- Holding company (As Per BSE Announcement Dated on 30.04.2024)
01-Feb-2024	09-Feb-2024	Quarterly Results	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 inter alia to consider and approve Pursuant to regulation 29 and 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as amended from time to time notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Friday February 9 2024 inter-alia to consider approve and take on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2023 Unaudited results for the quarter and nine months ended December 31, 2023 (As Per BSE Announcement Dated on 10.02.2024) we wish to inform you that the Board of Directors of the Company had at its meeting held today i.e., Friday, February 9, 2024, at 3:00 p.m. and concluded at 9:25 p.m., inter alia considered and approved the following: 1) Unaudited financials for the Quarter and nine months ended 31-12-2023 2)Statement of Deviation/ Variation in utilization of funds ('Statement') as at December 31,2023 3) Incorporation of Wholly Owned Subsidiary ('WOS') in Japan 4) issuance of Corporate Guarantee on behalf of Buli Chemicals India Private Limited, Wholly Owned Subsidiary (WOS) upto Rs. 50 crores and Others. (As Per BSE Announcement Dated on: 09/02/2024)
01-Nov-2023	08-Nov-2023	Accounts	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve Pursuant to regulation 29 and 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as amended from time to time notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday November 8 2023 inter-alia to consider approve and take on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2023. The Board of Directors of the Company had at its meeting held today i.e., Wednesday, November 8, 2023, inter alia considered and approved the following: 1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended September 30, 2023 2. Subscription of upto 40,00,000 equity shares at a price of Rs. 10 each on rights issue basis of its Wholly Owned Subsidiary i.e., Neogen Ionics Limited. 3.3. Investing by way of Loan up to Rs. 250 Crores in its Wholly Owned Subsidiary (WOS) i.e., Neogen Ionics Limited Approval of Financial Results for the Quarter and Half year ended September 30, 2023 by the Board of Directors in its meeting held on November 8 , 2023 (As per BSE Announcement Dated on 08/11/2023)
30-Sep-2023	05-Oct-2023	Preferential Issue	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/10/2023 inter alia to consider and approve Pursuant to regulation 29 of the Listing Regulations we wish to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday October 5 2023 inter alia to consider evaluate and approve the proposal for raising of funds by way of issue of equity shares in one or more tranche by way of a Preferential Issue. for a consideration and at such price as may be arrived at pursuant to Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations 2018 (each as amended from time to time) (ICDR Regulations) read with the applicable provisions of the Companies Act 2013. With regards to the captioned subject and pursuant to Regulation 30(2) read with Para A of Part A of Schedule III the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors at their meeting held today i.e. Thursday, October 5, 2023 which commenced at 7:45 P.M. and concluded at 9.45 p.m. inter alia, considered and approved: 1. Issuance of up to 14,42,358 Equity Shares of face value of Rs. 10 each ('Equity Shares') at a price of Rs. 1754.07 per Equity Share including a premium of Rs. 1744.07 per Equity Share, aggregating up to Rs. 2,52,99,96,897 (Rupees Two Hundred and Fifty Two Crore Ninety Nine Lakh Ninety Six Thousand Eight Hundred Ninety Seven only) (As per BSE Announcement Dated on 05/10/2023)
29-Jul-2023	05-Aug-2023	Quarterly Results	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2023 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on June 30 2023. The Board may in its meeting to be held on August 5, 2023 consider, evaluate and approve the alteration of Authorised Capital and consequent alteration of Memorandum of Association of the COmpany in accordance with the Applicable laws and subject to necessary approvals as may be required. (As Per BSE Announcement Dated on 02.08.2023) Board of Directors of the Company had at its meeting held today i.e. Saturday, August 5, 2023, considered and approved the items as mentioned in the attached outcome Board of Directors in its meeting held on August 5, 2023 approved the matters mentioned in the attachment (As Per BSE Announcement Dated on 05.08.2023)
06-May-2023	13-May-2023	Accounts	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2023 inter alia to consider and approve Pursuant to regulation 29 and 33 of the Listing Regulations notice is hereby given that a meeting of the Board of Directors of the Company is schedule to be held on Saturday May 13 2023 inter-alia to consider approve and take on record the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31 2023 and to consider recommendation of a final dividend if any on the equity shares of the Company for the financial year ended March 31 2023 subject to declaration and approval of the same by the shareholders at the ensuing Annual General Meeting. 1. Approved the Audited Financial Results (Standalone and Consolidated) of the Company along with the Audit Reports for the Quarter and Financial Year ended March 31, 2023, pursuant to Regulation 33 of the Listing Regulations, which has been duly reviewed and recommended by the Audit Committee; Pursuant to Regulation 33(3) (d) of the Listing Regulations, we would like to declare that the Statutory Auditors of the Company M/s. JMT & Associates, Chartered Accountants (FRN: 104167W) have issued the Auditors Report on Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2023 with un-modified opinion and a declaration to that effect is enclosed.2. Recommended a final dividend of Rs. 3 per Equity Share for the Financial Year 2022-23, subject to approval of shareholders at the ensuing Annual General Meeting of the Company. (As per BSE Announcement Dated on 13/05/2023)
10-Apr-2023	10-Apr-2023	Others	With regards to the captioned subject and in compliance with the Listing Regulations, we wish to inform you that the Board of Directors of Neogen Chemicals Limited ('Neogen') has at its meeting held today i.e. Monday, April 10, 2023 which commenced at 2.30 p.m. (IST) and concluded at 3.22 p.m.(IST), inter alia, considered and approved the execution of an agreement with MU Ionic Solutions Corporation ('MUIS'), Japan (a JV between Mitsubishi Chemical Corporation (MCC) and UBE Corporation and is a group company of The Mitsubishi Chemical Group (the group) a Japanese conglomerate) ('the Agreement'), to acquire manufacturing technology license for electrolytes in India subject to the terms and conditions as mentioned in the Agreement ('Transaction'). The details required under regulation 30 of the Listing Regulations, read with SEBI Circular No. CIR/CFD/CMD /4/2015 dated September 9, 2015 is attached herewith.
02-Mar-2023	04-Mar-2023	Acquisitions	This is to inform you that pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and the Company's Code of Conduct for Prohibition of Insider Trading ('Insider Trading Policy'), the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives/ Connected Persons/ Legitimate Insiders of the Company from Thursday, March 2, 2023 till the end of 48 hours after the conclusion of upcoming Board Meeting to be held on Saturday, March 4, 2023. With regards to the captioned subject and in compliance with the SEBI (LODR) Regulation 2015 we wish to inform you that the Board of Directors of Neogen Chemicals Limited at its meeting held today i.e. Saturday, March 4, 2023 which commenced at 7.15 p.m. (IST) and concluded at 8.50 p.m.(IST), inter alia, considered and approved, the acquisition of 4,69,26,000 (100%) Equity Shares of a face value of Rs. 10 each, of BuLi Chemicals India Private Limited ('BuLi Chem') for an amount up to Rs. 25,00,00,000 approximately, subject to final working capital adjustments on closing date ('Acquisition'). Further, the Board of Directors of the Company has approved the draft of Share Purchase Agreement ('SPA') which was placed before them, for purchase of 100% equity shares of BuLi Chem from Livent USA Corporation and Livent Corporation ('Selling Shareholders') subject to the terms of SPA. Pursuant to the said transaction BuLi Chem will become a Wholly Owned Subsidiary of the Company. (As per BSE Announcement Dated on 04/03/2023)
04-Feb-2023	11-Feb-2023	Quarterly Results	To consider and approve the financial results for the period ended December 31, 2022 Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2023 ,inter alia, to consider and approve Pursuant to regulation 29 of the Listing Regulations, notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Saturday, February 11, 2023, inter alia, to consider, approve and take on record the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2022, along with limited review report of the Statutory Auditors thereon. Further, as we have informed vide our letter dated December 31, 2022, the trading window closure period has commenced from Sunday, January 1, 2023 and will end 48 hours after the declaration of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2022 pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015. (As Per BSE Announcement Dated on 04.02.2023) we wish to inform you that the Board of Directors of Neogen Chemicals Limited ('the Company') at its meeting held today i.e. Saturday, February 11, 2023 which commenced at 3:00 p.m. (IST) and concluded at 9.15 p.m. (IST), inter alia, considered and approved: 1) The Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended December 31, 2022, pursuant to Regulation 33 of the Listing Regulations along with the 'Limited Review Report' thereon as submitted by the Statutory Auditors of the Company and duly reviewed and recommended by the Audit Committee 2) The incorporation of Wholly Owned Subsidiary ('WOS') with the name as may be approved by Registrar of Companies, Mumbai, Maharashtra with the main object to address growth opportunities in energy storage such as Lithium- Ion Battery material space and other future energy storage chemistries. The other details shall be intimated to the stock exchanges after the incorporation of the WOS. With regards to the captioned subject and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 (Listing Regulations), we wish to inform you that the Board of Directors of Neogen Chemicals Limited ('the Company') at its meeting held today i.e. Saturday, February 11, 2023 which commenced at 3.00 p.m. (IST) and concluded at 9.15 p.m. (IST), inter alia, considered and approved the incorporation of Wholly Owned Subsidiary ('WOS') with the name as may be approved by Registrar of Companies, Mumbai, Maharashtra with the main object to address growth opportunities in energy storage such as Lithium- Ion Battery material space and other future energy storage chemistries. The other details shall be intimated to the stock exchanges after the incorporation of the WOS. The Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended December 31, 2022, pursuant to Regulation 33 of the Listing Regulations along with the 'Limited Review Report' thereon as submitted by the Statutory Auditors of the Company and duly reviewed and recommended by the Audit Committee. (As Per BSE Announcement Dated on 11.02.2023)
29-Oct-2022	05-Nov-2022	Quarterly Results	Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2022 inter alia to consider and approve Pursuant to regulation 29 and 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as amended from time to time notice is hereby given that a meeting of the Board of Directors of the Company is schedule to be held on Saturday November 5 2022 inter-alia to consider approve and take on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30 2022. Further as we have informed vide our letter dated September 30 2022 the trading window closure period has commenced from Saturday October 1 2022 and will end 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and half year ended on September 30 2022 pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015. With reference to the captioned subject and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company had at its meeting held today i.e. Saturday, November 5, 2022, inter alia considered and approved the following: 1. the Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended September 30, 2022, along with the 'Limited Review Report' thereon as provided by the Statutory Auditors of the Company, which has been duly reviewed and recommended by the Audit Committee and the same is enclosed herewith; 2. we enclose herewith Statement of Deviation/ Variation in utilization of funds ('Statement') as at September 30, 2022, which has been duly reviewed by the Audit Committee. The Board Meeting commenced at 3.30 p.m. and concluded at 8.15 p.m. (As Per BSE Announcement Dated 05.11.2022)

1 2

LOGIN HERE

Neogen Chemicals Ltd

Board Meeting